Loading...

Brilliant Violet 421™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GK1.5_BV421_2_032911
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD4 (clone GK1.5) Brilliant Violet 421™ (left) or rat IgG2b, κ Brilliant Violet 421™ isotype control (right).
  • 1_GK1.5_BV421_2_032911
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD4 (clone GK1.5) Brilliant Violet 421™ (left) or rat IgG2b, κ Brilliant Violet 421™ isotype control (right).
  • 2_GK1.5_BV421_CD4_Antibody_IF_012914
    C57BL/6 mouse splenocytes were fixed with 2% paraformaldehyde (PFA), and then stained with 5 µg/ml CD4 (clone GK1.5) Brilliant Violet 421™ (blue) and 5 µg/ml CD19 (clone 6D5) Alexa Fluor® 647 (red) for 30 minutes at room temperature. The image was captured by 40X objective.
  • 3_52_Mouse_Liver_CD4_CD11c_CD11b
    Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD4 (yellow) in Cycle 1, CD11c (cyan) in Cycle 4, and CD11b (purple) in Cycle 4. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
100437 125 µL 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100443 50 µg 194€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100438 500 µL 300€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  2. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  3. Qi X, et al. 2022. FASEB J. 36:e22250. PubMed
  4. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  5. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  6. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  7. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  8. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  9. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  10. Jeon Y, et al. 2022. Cancers (Basel). 14:. PubMed
  11. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  12. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  13. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  14. Shinohara M 2015. J Immunol. 194:5595. PubMed
  15. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  16. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  17. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  18. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed
  19. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  20. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  21. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  22. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  23. Alberti D, et al. 2021. Curr Protoc. 1:e311. PubMed
  24. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  25. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  26. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  27. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  28. Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed
  29. Garg G et al. 2019. Cell reports. 26(7):1854-1868 . PubMed
  30. Goswami M, et al. 2019. Biomed Opt Express. 10:151. PubMed
  31. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  32. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  33. Marinescu CI, et al. 2021. Stem Cell Res Ther. 12:319. PubMed
  34. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  35. Li J, et al. 2020. Elife. 9:00. PubMed
  36. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  37. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  38. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  39. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  40. Ercoli G, et al. 2022. Clin Transl Immunology. 11:e1366. PubMed
  41. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  42. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  43. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  44. Hassan AO, et al. 2020. Cell. 183:169. PubMed
  45. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  46. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  47. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  48. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  49. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  50. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  51. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  52. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  53. Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed
  54. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  55. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  56. Silva DA, et al. 2019. Nature. 565:186. PubMed
  57. Bennion BG, et al. 2019. J Virol. 93. PubMed
  58. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  59. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  60. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  61. Li H, et al. 2022. iScience. 25:104481. PubMed
  62. Alam IS, et al. 2020. Cancer Res. 80:4780. PubMed
  63. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  64. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  65. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  66. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  67. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID
AB_10900241 (BioLegend Cat. No. 100437)
AB_10900241 (BioLegend Cat. No. 100443)
AB_10900241 (BioLegend Cat. No. 100438)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 3    Revision Date: 04/21/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account